GlycoOptimized GT-MAB 2.5-GEX™

PankoMab-GEX™ is a potent humanized and glycooptimized therapeutic antibody (IgG1) recognizing Glycotope’s novel carbohydrate-induced conformational TA-MUC1 epitope expressed on the majority of tumor cells in a wide variety of cancers. The epitope comprises a tumor-specific carbohydrate antigen together with the immunodominant peptide region of MUC1, combining high tumor-specificity, high number of binding sites and affinity. It is abundantly present on primary tumors, metastasis and cancer stem cells and virtually absent on normal cells. Main target indications include ovarian, lung, breast and gastrointestinal tumors, and other, mostly with over 90% of the patients and tumor cells. PankoMab-GEX™ expresses a series of potent anti-tumor modes of action, including antibody-dependent cellular cytotoxicity (ADCC), tumor cell phagocytosis and apoptosis induction, strongly enhanced by glycooptimization through Glycotope’s GlycoExpress™ platform. This allows a significantly improved treatment outcome compared to non-glycooptimized biotherapeutics. PankoMab-GEX™ is the lead molecule of Glycotopes’s GlycoBody technology which represents the Company’s treasure box of more than 200 monoclonal antibodies. GT-MAB 2.5-GEX™ is a novel exceptionally potent anti-tumor specific antibody (GlycoBody) developed by GlycoDesign and GlycoOptimization, currently in Clinical Phase IIb started in Q3 / 2013.